Granisetron Transdermal System

摘要

Granisetron transdermal system is indicated for the preventionof nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days.1 (See Table 1 for a comparison of the indications approved by the US Food and Drug Administration [FDA] for the 5-HT_3 antagonists.)